Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.4 - $0.56 $412,106 - $576,949
-1,030,267 Reduced 34.2%
1,982,341 $792,000
Q1 2024

May 15, 2024

BUY
$0.53 - $1.89 $1.6 Million - $5.69 Million
3,012,608 New
3,012,608 $1.6 Million

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $68.5M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.